At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- NNC0487-0111 (drug), Placebo (matched to NNC0487-0111) (drug)
- How long the study runs
- Study runs about 42 months (dates as stated)
- About the drug or intervention
- NNC0487-0111 — drug: NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm. · Placebo (matched to NNC0487-0111) — drug: Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 1,150
- Started
- 2026-02-24
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for obesity
- • Phase3 - 1,150 participants
- • The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with obesity
Where?
- • Fowey - Fowey River Practice
- • Poole - The Adam Practice
- • Macclesfield - EMS Healthcare
- • Pickering - Pickering Medical Practice
- • +8 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Male or female (sex at birth).
- ✓History of at least one self-reported unsuccessful dietary effort to lose body weight.
Who cannot take part
- ✗HbA1c ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening.
- ✗History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
- ✗Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP)...
See the full criteria
Where Is This Study? (12 UK sites)
Fowey River Practice
Fowey PL23 1DT, United Kingdom
The Adam Practice
Poole BH16 5PW, United Kingdom
EMS Healthcare
Macclesfield SK10 4TF, United Kingdom
Pickering Medical Practice
Pickering YO18 8BL, United Kingdom
The Crouch Oak Family Practice
Addlestone KT15 2BH, United Kingdom
The Health Centre
Bradford on Avon BA15 1DQ, United Kingdom
HMC Health - Heston - The Meadows Centre for Health
Hounslow TW4 7NJ, United Kingdom
Kiltearn Medical Centre
Nantwich CW5 5NX, United Kingdom
Knowle House Surgery
Plymouth PL5 3JB, United Kingdom
Clifton Medical Centre
Rotherham S65 1DA, United Kingdom
Staploe Medical Centre
Soham CB7 5JD, United Kingdom
Albany House Medical Centre
Wellingborough NN8 4RW, United Kingdom
How to Get in Touch
Novo Nordisk
Sponsor contactCONTACT